Clinical Trial Update: The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in patients with gynecologic malignancies; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Gynecologic Malignancies

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Chemotherapy-induced Thrombocytopenia | Phase 2 | Status: UNKNOWN